可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Ross R.The pathogenesis of atherosclerosis:a perspective for the 1990s[J]. Nature, 1993, 362(6423):801-809.
[2] 周启林,田国平.CD40CD40L与急性冠脉综合征的研究进展[J].心脏杂志,2006,18(2):239-241.
[3] 袁铭,吴宗贵,黄佐,等.高血压并发症与患者血清可溶性CD40及CD40L水平的关系[J].心脏杂志,2006,18(2):231-233.
[4] Viallard JF, Solanilla A, Gauthier B, et al.Increased soluble and platelet associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis [J].Blood, 2002, 99(7):2612-2614.
[5] Lutgens E,Cleutjens KB, Heeneman S, et al, Both early and delayed antiCD40L antibody treatment induces a stable plaque phenotype [J].Proc Natl Acad Sci USA, 2000,97(13):7464-7469.
[6] Phipps RP, Koumas L, Leung E, et al. The CD40CD40 ligand system: a potential therapeutic target in atherosclerosis[J]. Curr Opin Investig Drugs, 2001, 2(6):773-777.
[7] Lee Y,Lee WH,Lee SC,et al.CD40L activation in circulation platelets in patients with acute coronary syndrome [J].Cardiology,1999,92(1):11-16.
[8] 陈颖敏,宋玮,刘建平,等. 通心络治疗急性冠脉综合征对血清sCD40L的影响[J].上海第二医科大学学报,2005,25(7):727-729.
[9] Aukrust P,Mller F,Ueland T,et al.Enlanced levels of soluble and membrancebound CD40 ligand in patients with unstable anginepossible reflection of lymphocyte and platelet involvement in the pathogenesis of acute coronary syndrome [J]. Circulation, 1999, 100(6):614-620.